EMMA DAVIS: Open Payments
NPI 1861262479 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$820 in 33 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $815 · 2025 $820
Food & beverage: $820
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 6 | $195 |
| Novo Nordisk Inc | 4 | $182 |
| PFIZER INC. | 6 | $125 |
| ABBVIE INC. | 4 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $34 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Optinose US, Inc. | 1 | $27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
Products named: REPATHA, Wegovy, NURTEC ODT, CAPLYTA, Kerendia, OTEZLA, VRAYLAR, REXULTI.
Industry payments across VA — which companies pay providers there.
